NASDAQ:LGND Ligand Pharmaceuticals - LGND Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $71.70 +1.65 (+2.36%) (As of 02/3/2023 11:01 AM ET) Add Compare Share Share Today's Range$69.45▼$71.9150-Day Range$62.15▼$76.6152-Week Range$57.77▼$128.51Volume19,025 shsAverage Volume101,510 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$119.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ligand Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside66.9% Upside$119.00 Price TargetShort InterestBearish5.06% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment1.21Based on 3 Articles This WeekInsider TradingSelling Shares$1.53 M Sold Last QuarterProj. Earnings Growth-44.68%From $2.35 to $1.30 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.27 out of 5 starsMedical Sector271st out of 1,029 stocksPharmaceutical Preparations Industry129th out of 501 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.00, Ligand Pharmaceuticals has a forecasted upside of 66.9% from its current price of $71.32.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.06% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently increased by 1.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 3.4 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ligand Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest7 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,530,185.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.16% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to decrease by -44.68% in the coming year, from $2.35 to $1.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is -57.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is -57.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 2.18. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ligand Pharmaceuticals (NASDAQ:LGND) StockLigand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.Read More Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Down 7% January 23, 2023 | finance.yahoo.comShareholders in Ligand Pharmaceuticals (NASDAQ:LGND) are in the red if they invested five years agoFebruary 3, 2023 | Investing Trends (Ad)Apple, Amazon, and Walmart are Investing in Solar EnergyThe global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 11, 2023 | finance.yahoo.comAre Options Traders Betting on a Big Move in Ligand (LGND) Stock?January 6, 2023 | finance.yahoo.comLigand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum ContagiosumDecember 23, 2022 | msn.comRoth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To KnowDecember 19, 2022 | finance.yahoo.comAre Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?December 13, 2022 | markets.businessinsider.comLigand Pharma Guides FY23 EPS Above View, But Revenue Shy Of EstimatesFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 13, 2022 | finance.yahoo.comLigand Provides Highlights from its Investor and Analyst Day EventDecember 13, 2022 | finance.yahoo.comIs BioNTech (BNTX) Stock Undervalued Right Now?December 13, 2022 | finance.yahoo.comLGND or GMAB: Which Is the Better Value Stock Right Now?December 13, 2022 | finance.yahoo.comLigand Pharma Issues Mixed Guidance For FY23December 8, 2022 | finance.yahoo.comSermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into PracticeDecember 5, 2022 | marketwatch.comLigand Pharmaceuticals CEO Higgins RetiresDecember 5, 2022 | nasdaq.comIs Now The Time OmniAb? 5 Insider Purchase And Two Bullish Initiations Propel Shares Almost 100% Higher Over The WeekDecember 5, 2022 | seekingalpha.comOmniAb: Scalable Biotech Spinoff Opportunity, High Risk/High RewardNovember 17, 2022 | finance.yahoo.comSermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer SymposiumNovember 16, 2022 | finance.yahoo.comLigand to Hold Investor and Analyst Day on December 13November 15, 2022 | finance.yahoo.comOmniAb Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 8, 2022 | finance.yahoo.comLigand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 OutlookNovember 8, 2022 | markets.businessinsider.comLigand Pharmaceuticals Inc Q3 Profit Decreases, but beats estimatesNovember 8, 2022 | finance.yahoo.comLigand Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | finance.yahoo.comLigand Pharmaceuticals (LGND) Misses Q3 Earnings EstimatesNovember 4, 2022 | msn.comEarnings Outlook For Ligand PharmaceuticalsNovember 2, 2022 | finance.yahoo.comIs There An Opportunity With Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) 50% Undervaluation?November 1, 2022 | finance.yahoo.comLigand Announces Completion of OmniAb Spin-OffSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Company Calendar Last Earnings11/07/2022Today2/03/2023Next Earnings (Estimated)2/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees154Year FoundedN/APrice Target and Rating Average Stock Price Forecast$119.00 High Stock Price Forecast$160.00 Low Stock Price Forecast$90.00 Forecasted Upside/Downside+66.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.24) Trailing P/E RatioN/A Forward P/E Ratio30.51 P/E Growth2.18Net Income$57.14 million Net Margins-8.62% Pretax Margin-11.15% Return on Equity2.57% Return on Assets1.84% Debt Debt-to-Equity RatioN/A Current Ratio1.63 Quick Ratio1.46 Sales & Book Value Annual Sales$277.13 million Price / Sales4.37 Cash Flow$8.98 per share Price / Cash Flow7.98 Book Value$49.14 per share Price / Book1.46Miscellaneous Outstanding Shares16,890,000Free Float15,137,000Market Cap$1.21 billion OptionableOptionable Beta1.07 Key ExecutivesTodd C. DavisChief Executive Officer & DirectorMatthew Edward KorenbergPresident & Chief Operating OfficerOctavio EspinozaChief Financial OfficerEric VajdaVice President-Preclinical Research & DevelopmentSimon LatimerInvestors Relations ManagerKey CompetitorsGeronNASDAQ:GERNOPKO HealthNASDAQ:OPKImmunoGenNASDAQ:IMGNMannKindNASDAQ:MNKDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsKornitzer Capital Management Inc. KSSold 18,940 shares on 2/2/2023Ownership: 0.632%Smith Graham & Co. Investment Advisors LPSold 20,485 shares on 2/2/2023Ownership: 0.387%Monarch Partners Asset Management LLCBought 2,743 shares on 2/2/2023Ownership: 0.369%SG Americas Securities LLCBought 37,838 shares on 2/2/2023Ownership: 0.224%ProShare Advisors LLCBought 284 shares on 2/2/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions LGND Stock - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price forecast for 2023? 4 equities research analysts have issued 12-month price objectives for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $160.00. On average, they expect the company's stock price to reach $119.00 in the next twelve months. This suggests a possible upside of 69.9% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2023? Ligand Pharmaceuticals' stock was trading at $66.80 on January 1st, 2023. Since then, LGND shares have increased by 4.9% and is now trading at $70.05. View the best growth stocks for 2023 here. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings results on Monday, November, 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.29. The biotechnology company had revenue of $66.09 million for the quarter, compared to analyst estimates of $38.47 million. Ligand Pharmaceuticals had a positive trailing twelve-month return on equity of 2.57% and a negative net margin of 8.62%. What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, December, 21st. The company provided earnings per share guidance of $4.30-$4.45 for the period, compared to the consensus EPS estimate of $4.24. The company issued revenue guidance of $184.00 million-$189.00 million, compared to the consensus revenue estimate of $212.82 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." Who are Ligand Pharmaceuticals' major shareholders? Ligand Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Villere ST Denis J & Co. LLC (2.86%), Stephens Investment Management Group LLC (2.69%), Chicago Capital LLC (1.89%), Rice Hall James & Associates LLC (1.69%), Kornitzer Capital Management Inc. KS (0.63%) and Smith Graham & Co. Investment Advisors LP (0.39%). Insiders that own company stock include Charles S Berkman, John L Higgins, John W Kozarich, Matthew W Foehr, Octavio Espinoza and Todd C Davis. View institutional ownership trends. How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $70.05. How much money does Ligand Pharmaceuticals make? Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.18 billion and generates $277.13 million in revenue each year. The biotechnology company earns $57.14 million in net income (profit) each year or ($1.24) on an earnings per share basis. How many employees does Ligand Pharmaceuticals have? The company employs 154 workers across the globe. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826. This page (NASDAQ:LGND) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.